Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other 2Gynecologic 1

Conditions

Constipation 6Intestinal Diseases 5Pain 3Neoplasms 3Urinary Bladder Neoplasms 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Opioid-Induced Constipation 1Ileus 1Fallopian Tube Neoplasms 1Cancer Pain 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × alvimopan × Clear all
NCT01704651 2016-10-24

Accelerating Gastrointestinal Recovery

Mayo Clinic

Phase 3 Completed
146 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
67 enrolled
Other

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

NCT00331045 2015-09-02

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
21 enrolled
Other

Constipation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡